Get the most updated and recent current affair content on

First Nasal Vaccine Developed by Bharat Biotech

  • Integrity Education, Delhi
  • 14, Aug 2021
Image Not Found

  • Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2 trials.
  • BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
  • BBIL has in-licensed technology from Washington University in St Louis, USA. 
  • The development of the vaccine is supported by the Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC)
  • Mission COVID Suraksha was launched to reinforce and accelerate COVID-19 vaccine development efforts under Atmanirbhar 3.0.